NIBEC, a DBT-supported facility for viral immunogenicity testing inaugurated
Context:
The National Immunogenicity and Biologics Evaluation Centre (NIBEC) for assessing clinical immunogenicity of viral vaccines, especially the ones in the pipeline for Covid19, has been inaugurated.
About:
Established jointly by Bharati Vidyapeeth University through its constituent unit Interactive Research School for Health Affairs (IRSHA) and BIRAC-DBT, Government of India through “Innovate in India (i3) program under National Biopharma Mission.
Immunogenicity refers to the ability of a drug to induce an immune response and is a concern for peptide and protein therapeutics. Preclinical immunogenicity is not predictive of immunogenicity in humans, but it helps to understand the findings in a toxicology study and therefore is an important factor in vaccine development
What is National Biopharma Mission?
This mission would aid in enhancing India’s innovation research and product development capabilities, especially by focusing on the development of vaccines, biologics, and medical devices for combating public health concerns.
It is an Industry-Academia Collaborative Mission of the Department of Biotechnology (DBT) for Accelerating Early Development for Biopharmaceuticals.
The mission is implemented by Biotechnology Research Assistance Council (BIRAC).
Innovate in India (I3)
The program named Innovate in India (I3) is an industry-academia collaborative mission of the Department of Biotechnology (DBT) in collaboration with the World Bank for accelerating discovery research to the early development of Biopharmaceuticals and to be implemented by the Biotechnology Industry Research Assistance Council (BIRAC).
Biotechnology Industry Research Assistance Council (BIRAC)
Biotechnology Industry Research Assistance Council (BIRAC) is a not-for-profit Section 8, Schedule B, Public Sector Enterprise.
It is set up by the Department of Biotechnology (DBT) as an Interface Agency to strengthen and empower the emerging Biotech enterprise to undertake strategic research and innovation, addressing nationally relevant product development needs.
NIBEC, a DBT-supported facility for viral immunogenicity testing inaugurated
Context:
The National Immunogenicity and Biologics Evaluation Centre (NIBEC) for assessing clinical immunogenicity of viral vaccines, especially the ones in the pipeline for Covid19, has been inaugurated.
About:
Immunogenicity refers to the ability of a drug to induce an immune response and is a concern for peptide and protein therapeutics. Preclinical immunogenicity is not predictive of immunogenicity in humans, but it helps to understand the findings in a toxicology study and therefore is an important factor in vaccine development
What is National Biopharma Mission?
Innovate in India (I3)
The program named Innovate in India (I3) is an industry-academia collaborative mission of the Department of Biotechnology (DBT) in collaboration with the World Bank for accelerating discovery research to the early development of Biopharmaceuticals and to be implemented by the Biotechnology Industry Research Assistance Council (BIRAC).
Biotechnology Industry Research Assistance Council (BIRAC)